Destructive cycles: The role of genomic instability and adaptation in carcinogenesis

Carcinogenesis

Volumn 25, Issue 11, 2004, Pages 2033-2044

  Schneider, Brandt L ^a   Kulesz Martin, Molly ^b  

^a TEXAS TECH UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN;

ADAPTATION; ANEUPLOIDY; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CELL CYCLE; CELL POPULATION; CELL SELECTION; EPIGENETICS; GENETIC HETEROGENEITY; GENETIC STABILITY; HOMEOSTASIS; HUMAN; LATENT PERIOD; MICROENVIRONMENT; MUTAGENESIS; MUTATION RATE; NONHUMAN; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TUMOR CELL;

ANIMALS; CARCINOGENS; CELL DIVISION; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HOMEOSTASIS; HUMANS; MUTATION; NEOPLASMS;

EID: 8844279091     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh204     Document Type: Review

References (200)

1. Hahn,W.C. and Weinberg,R.A. (2002) Modelling the molecular circuitry of cancer. Nature Rev. Cancer, 2, 331-341.
2. Hanahan,D. and Weinberg,R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70.
3. Hahn,W.C. and Weinberg,R.A. (2002) Rules for making human tumor cells. N. Engl. J. Med., 347, 1593-1603.
4. Medema,R.H. and Bos,J.L. (1993) The role of p21ras in receptor tyrosine kinase signaling. Crit. Rev. Oncogen., 4, 615-661.
5. Hickman,E.S., Moroni,M.C. and Helin,K. (2002) The role of p53 and pRB in apoptosis and cancer. Curr. Opin. Genet. Dev., 12, 60-66.
6. Gao,X., Neufeld,T.P. and Pan,D. (2000) Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. Dev. Biol., 221, 404-418.
7. Harris,C.C. (1996) p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis, 17, 1187-1198.
8. Alberts,B. (2002) Molecular Biology of the Cell. Garland Science, New York, NY.
9. Duesberg,P. and Li,R. (2003) Multistep carcinogenesis: a chain reaction of aneuploidizations. Cell Cycle, 2, 202-210.
10. Armitage,P. and Doll,R. (1954) The age distribution of cancer and a multistage theory of carcinogenesis. Br. J. Cancer, 8, 1-12.
11. Cairns,J. (1978) Cancer: Science and Society. W.H. Freeman, San Francisco, CA.
12. Foulds,L. (1969) Neoplastic Development. Academic Press, London.
13. Vogelstein,B. and Kinzler,K.W. (1993) The multistep nature of cancer. Trends Genet., 9, 138-141.
14. Rew,D.A. and Wilson,G.D. (2000) Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur. J. Surg. Oncol., 26, 405-417.
15. Al-Hajj,M. Wicha,M.S., Benito-Hernandez,A., Morrison,S.J. and Clarke,M.F. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA, 100, 3983-3988.
16. Reya, T., Morrison,S.J., Clarke,M.F. and Weissman,I.L. (2001) Stem cells, cancer and cancer stem cells. Nature, 414, 105-111.
17. Newbold,R.F. and Overell,R.W. (1983) Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304, 648-651.
18. Perez-Losada,J. and Balmain,A. (2003) Stem-cell hierarchy in skin cancer. Nature Rev. Cancer, 3, 434-443.
19. Hahn,W.C., Counter,C.M., Lundberg,A.S., Beijersbergen,R.L., Brooks,M.W. and Weinberg,R.A. (1999) Creation of human tumour cells with defined genetic elements. Nature, 400, 464-468.
20. Elenbaas,B., Spirio,L., Koerner,F., Fleming,M.D., Zimonjic,D.B., Donaher,J.L., Popescu,N.C., Hahn,W.C. and Weinberg,R.A. (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev., 15, 50-65.
21. Chen,W., Possemato,R., Campbell,K.T., Plattner,C.A., Pallas,D.C. and Hahn,W.C. (2004) Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell, 5 127-136.
22. Chen,W. and Hahn,W.C. (2003) SV40 early region oncoproteins and human cell transformation. Histol. Histopathol., 18, 541-550.
23. Hahn,W.C., Dessain,S.K., Brooks,M.W., King,J.E., Elenbaas,B., Sabatini,D.M., DeCaprio,J.A. and Weinberg,R.A. (2002) Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol., 22, 2111-2123.
24. Colgin,L.M. and Reddel,R.R. (1999) Telomere maintenance mechanisms and cellular immortalization. Curr. Opin. Genet. Dev., 9, 97-103.
25. Gonzalez-Suarez,E., Samper,E., Ramirez,A., Flores,J.M., Martin-Caballero,J., Jorcano,J.L. and Blasco,M.A. (2001) Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J., 20, 2619-2630.
26. Blasco,M.A. (2002) Telomerase beyond telomeres. Nature Rev. Cancer, 2, 627-633.
27. Rous,P. (1959) Surmise and fact on the nature of cancer. Nature, 183, 1357-1361.
28. Bishop,J.M. (1995) Cancer: the rise of the genetic paradigm. Genes Dev., 9, 1309-1315.
29. Rubin,H. (1999) Cell damage, aging and transformation: a multilevel analysis of carcinogenesis. Anticancer Res., 19, 4877-4886.
30. Vineis,P. (2003) Cancer as an evolutionary process at the cell level: an epidemiological perspective. Carcinogenesis, 24 1-6.
31. Schwab,E.D. and Pienta,K.J. (1996) Cancer as a complex adaptive system. Med. Hypotheses, 47, 235-241.
32. Li,R., Sonik,A., Stindl,R., Rasnick,D. and Duesberg,P. (2000) Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. Proc. Natl Acad. Sci. USA 97, 3236-3241.
33. Duesberg,P., Li,R., Rasnick,D., Rausch,C., Willer,A., Kraemer,A., Yerganian,G. and Hehlmann,R. (2000) Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet. Cytogenet., 119, 83-93.
34. Duesberg,P., Rasnick,D., Li,R., Winters,L., Rausch,C. and Hehlmann,R. (1999) How aneuploidy may cause cancer and genetic instability. Anticancer Res., 19, 4887-4906.
35. Steen,H.B. (2000) The origin of oncogenic mutations: where is the primary damage? Carcinogenesis, 21, 1773-1776.
36. Rubin,H. (2002) Selective clonal expansion and microenvironmental permissiveness in tobacco carcinogenesis. Oncogene 21, 7392-7411.
37. Rubin,H. (1990) The significance of biological heterogeneity. Cancer Metastasis Rev., 9, 1-20.
38. Bignold,L.P. (2003) Initiation of genetic instability and tumour formation: a review and hypothesis of a nongenotoxic mechanism. Cell Mol. Life Sci., 60, 1107-1117.
39. Rasnick,D. (2002) Aneuploidy theory explains tumor formation, the absence of immune surveillance and the failure of chemotherapy. Cancer Genet. Cytogenet., 136, 66-72.
40. Duesberg,P. and Rasnick,D. (2000) Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil. Cytoskeleton, 47, 81-107.
41. Renan,M.J. (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog., 7, 139-146.
42. Seo,K.Y., Jelinsky,S.A. and Loechler,E.L. (2000) Factors that influence the mutagenic patterns of DNA adducts from chemical carcinogens. Murat. Res., 463, 215-246.
43. Kozack,R., Seo,K.Y., Jelinsky,S.A. and Loechler,E.L. (2000) Toward an understanding of the role of DNA adduct conformation in defining mutagenic mechanism based on studies of the major adduct (formed at N(2)-dG) of the potent environmental carcinogen, benzo[a]pyrene. Mutat. Res., 450, 41-59.
44. Yuspa,S.H. and Shields,P.G. (1997) Etiology of cancer. Chemical factors. In Devita,V.T.,Jr, Hellman,S. and Rosenberg,S.A. (eds) Cancer, Principles and Practice of Oncology. Lippincott Co., Philadelphia, PA, pp. 185-202.
45. Povey,A.C. (2000) DNA adducts: endogenous and induced. Toxicol. Pathol., 28, 405-414.
46. Bartsch,H. (1996) DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. Mutat. Res. 340, 67-79.
47. Cooper,D.P., O'Connor,P.J., Povey,A.C. and Rafferty,J.A. (1995) Cell and molecular mechanisms in chemical carcinogenesis. In Peckham,M.J., Pinedo,H.M. and Veronesi,U. (eds) Oxford Textbook of Oncology. Oxford University Press, Oxford, pp. 135-147.
48. Garner,R.C. (1998) The role of DNA adducts in chemical carcinogenesis. Mutat. Res., 402, 67-75.
49. Fabarius,A., Willer,A., Yerganian,G., Hehlmann,R. and Duesberg,P. (2002) Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea. Proc. Natl Acad. Sc USA, 99, 6778-6783.
50. Chu,E.H., Trosko,J.E. and Chang,C.C. (1977) Mutational approaches to the study of carcinogenesis. J. Toxicol Environ. Health 2, 1317-1334.
51. Zeiger,E. (2001) Mutagens that are not carcinogens: faulty theory or faulty tests? Mutat. Res., 492, 29-38.
52. Gold,L.S., Slone,T.H., Stern,B.R. and Bernstein,L. (1993) Comparison of target organs of carcinogenicity for mutagenic and non-mutagenic chemicals. Mutat. Res., 286, 75-100.
53. Klein,C.B. and Costa,M. (1997) DNA methylation, heterochromatin and epigenetic carcinogens. Mutat. Res., 386, 163-180.
54. Brown,K., Buchmann,A. and Balmain,A. (1990) Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc. Natl Acad. Sci. USA 87, 538-542.
55. Quintanilla,M., Brown,K., Ramsden,M. and Balmain,A. (1986) Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature, 322, 78-80.
56. Zarbl,H., Sukumar,S., Arthur,A.V., Martin-Zanca,D. and Barbacid,M. (1985) Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature, 315, 382-385.
57. Hussain,S.P., Hollstein,M.H. and Harris,C.C. (2000) p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Ann. N. Y. Acad. Sci., 919, 79-85.
58. Rodin,S.N. and Rodin,A.S. (2000) Human lung cancer and p53: the interplay between mutagenesis and selection. Proc. Natl Acad. Sci. USA, 97, 12244-12249.
59. Rodin,S.N. and Rodin,A.S. (2002) On the origin of p53 G:C→T:A transversions in lung cancers. Mutat. Res., 508, 1-19.
60. Denissenko,M.F., Koudriakova,T.B., Smith,L., O'Connor,T.R., Riggs,A.D. and Pfeifer,G.P. (1998) The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene, 17, 3007-3014.
61. Cha,R.S., Guerra,L., Thilly,W.G. and Zarbl,H. (1996) Ha-ras-1 oncogene mutations in mammary epithelial cells do not contribute to initiation of spontaneous mammary tumorigenesis in rats. Carcinogenesis, 17, 2519-2524.
62. Cha,R.S., Thilly,W.G. and Zarbl,H. (1994) N-nitroso-N-methylurea-induced rat mammary tumors arise from cells with preexisting oncogenic Hras1 gene mutations. Proc. Natl Acad. Sci. USA 91, 3749-3753.
63. Whiteman,D.C., Whiteman,C.A. and Green,A.C. (2001) Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control, 12, 69-82.
64. Noonan,F.P., Dudek,J., Merlino,G. and De Fabo,E.C. (2003) Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events. Pigment Cell Res., 16, 16-25.
65. Denissenko,M.F., Pao,A., Tang,M. and Pfeifer,G.P. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430-432.
66. Quintanilla,M., Haddow,S., Jonas,D., Jaffe,D., Bowden,G.T. and Balmain,A. (1991) Comparison of ras activation during epidermal carcinogenesis in vitro and in vivo. Carcinogenesis, 12 1875-1881.
67. Campisi,J. (2003) Cancer and ageing: rival demons? Nature Rev. Cancer, 3, 339-349.
68. DePinho,R.A. (2000) The age of cancer. Nature, 408 248-254.
69. Marsh,D. and Zori,R. (2002) Genetic insights into familial cancers - update and recent discoveries. Cancer Lett., 181, 125-164.
70. Jonason,A.S., Kunala,S., Price,G.J., Restifo,R.J., Spinelli,H.M., Persing,J.A., Leffell,D.J., Tarone,R.E. and Brash,D.E. (1996) Frequent clones of p53-mutated keratinocytes in normal human skin. Proc. Natl Acad. Sci. USA, 93, 14025-14029.
71. Kraemer,K.H. (1997) Sunlight and skin cancer: another link revealed. Proc. Natl Acad. Sci. USA, 94, 11-14.
72. Mori,H., Colman,S.M., Xiao,Z., Ford,A.M., Healy,L.E., Donaldson,C., Hows,J.M., Navarrete,C. and Greaves,M. (2002) Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl Acad. Sci. USA, 99, 8242-8247.
73. Hennings,H., Spangler,E.F., Shores,R., Mitchell,P., Devor,D., Shamsuddin,A.K., Elgjo,K.M. and Yuspa,S.H. (1986) Malignant conversion and metastasis of mouse skin tumors: a comparison of SENCAR and CD-1 mice. Environ. Health Perspect., 68, 69-74.
74. Umayahara,K., Numa,F., Suehiro,Y. et al. (2002) Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosom. Cancer 33, 98-102.
75. Deng,G., Chen,L.C., Schott,D.R., Thor,A., Bhargava,V., Ljung,B.M., Chew,K. and Smith,H.S. (1994) Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res., 54, 499-505.
76. Aubele,M., Mattis,A., Zitzelsberger,H., Walch,A., Kremer,M., Welzl,G., Hofler,H. and Werner,M. (2000) Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int. J. Cancer, 85, 82-86.
77. O'Neill,G.M., Catchpoole,D.R. and Golemis,E.A. (2003) From correlation to causality: microarrays, cancer and cancer treatment. Biotechniques, (suppl.), 64-71.
78. Zhang,L., Zhou,W., Velculescu,V.E., Kern,S.E., Hruban,R.H., Hamilton,S.R., Vogelstein,B. and Kinzler,K.W. (1997) Gene expression profiles in normal and cancer cells. Science, 276, 1268-1272.
79. Nowell,P.C. (1976) The clonal evolution of tumor cell populations. Science, 194, 23-28.
80. Duesberg,P., Stindl,R. and Heldmann,R. (2001) Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc. Natl Acad. Sci. USA, 98, 11283-11288.
81. Duesberg,P., Stindl,R. and Hehlmann,R. (2000) Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc. Natl Acad. Sci. USA, 97, 14295-14300.
82. Shih,I.M., Zhou,W., Goodman,S.N., Lengauer,C., Kinzler,K.W. and Vogelstein,B. (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res., 61, 818-822.
83. Lengauer,C., Kinzler,K.W. and Vogelstein,B. (1998) Genetic instabilities in human cancers. Nature, 396, 643-649.
84. Heppner,G.H. and Miller,F.R. (1998) The cellular basis of tumor progression. Int. Rev. Cytol., 177, 1-56.
85. Heim,S. and Mitelman,F. (1995) Cancer Cytogenetics. Wiley-Liss, New York, NY.
86. Sandberg,A.A. (1990) The Chromosomes in Human Cancer and Leukemia. Elsevier, New York, NY.
87. Boveri,T. (1914) Zur Frage der Enstehung maligner Tumoren [On the Question of the Origin of Malignant Tumors]. Fischer, Jena.
88. Fabarius,A., Hehlmann,R. and Duesberg,P.H. (2003) Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet. Cytogenet, 143, 59-72.
89. Hasty,P., Campisi,J., Hoeijmakers,J., van Steeg,H. and Vijg,J. (2003) Aging and genome maintenance: lessons from the mouse? Science, 299, 1355-1359.
90. Pihan,G.A., Wallace,J., Zhou,Y. and Doxsey,S.J. (2003) Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res., 63, 1398-1404.
91. Bardelli,A., Cahill,D.P., Lederer,G., Speicher,M.R., Kinzler,K.W., Vogelstein,B. and Lengauer,C. (2001) Carcinogen-specific induction of genetic instability. Proc. Natl Acad. Sci. USA, 98 5770-5775.
92. Kramer,A., Neben,K. and Ho,A.D. (2002) Centrosome replication, genomic instability and cancer. Leukemia, 16, 767-775.
93. Matzke,M.A., Mette,M.F., Kanno,T. and Matzke,A.J. (2003) Does the intrinsic instability of aneuploid genomes have a causal role in cancer? Trends Genet., 19, 253-256.
94. Sen,S. (2000) Aneuploidy and cancer. Curr. Opin. Oncol. 12, 82-88.
95. Bialy,H. (2001) Aneuploidy and cancer - the vintage wine revisited. Nat. Biotechnol., 19, 22-23.
96. Stock,R.P. and Bialy,H. (2003) The sigmoidal curve of cancer. Nat. Biotechnol., 21, 13-14.
97. Ruggero,D. and Pandolfi,P.P. (2003) Does the ribosome translate cancer? Nature Rev. Cancer, 3, 179-192.
98. Vineis,P., Matullo,G. and Manuguerra,M. (2003) An evolutionary paradigm for carcinogenesis? J. Epidemiol. Community Health, 57, 89-95.
99. Marx,J. (2002) Debate surges over the origins of genomic defects in cancer. Science, 297, 544-546.
100. Anderson,G.R., Stoler,D.L. and Brenner,B.M. (2001) Cancer: the evolved consequence of a destabilized genome. Bioessays, 23 1037-1046.
101. Stoler,D.L., Chen,N., Basik,M., Kahlenberg,M.S., Rodriguez-Bigas,M.A., Petrelli,N.J. and Anderson,G.R. (1999) The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl Acad. Sci. USA, 96, 15121-15126.
102. Boland,C.R. and Ricciardiello,L. (1999) How many mutations does it take to make a tumor? Proc. Natl Acad. Sci. USA, 96, 14675-14677.
103. Mitelman,F., Johansson,B. and Mertens,F. (1994) Catalog of Chromosome Aberrations in Cancer. Wiley-Liss, New York, NY.
104. Fodde,R. and Smits,R. (2002) Cancer biology. A matter of dosage. Science, 298, 761-763.
105. Sheff,C.J. (2004) Principles of tumor suppression. Cell 116, 235-246.
106. Albertson,D.G., Collins,C., McCormick,F. and Gray,J.W. (2003) Chromosome aberrations in solid tumors. Nature Genet., 34, 369-376.
107. Loeb,L.A. (2001) A mutator phenotype in cancer. Cancer Res., 61, 3230-3239.
108. Loeb,L.A., Loeb,K.R. and Anderson,J.P. (2003) Multiple mutations and cancer. Proc. Natl Acad. Sci. USA, 100, 776-781.
109. Barrett,M.T., Sanchez,C.A., Prevo,L.J., Wong,D.J., Galipeau,P.C., Paulson,T.G., Rabinovitch,P.S. and Reid,B.J. (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nature Genet., 22, 106-109.
110. Sudbo,J., Kildal,W., Risberg,B., Koppang,H.S., Danielsen,H.E. and Reith,A. (2001) DNA content as a prognostic marker in patients with oral leukoplakia. N. Engl. J. Med., 344, 1270-1278.
111. Lindberg,J.O., Stenling,R.B. and Rutegard,J.N. (1999) DNA aneuploidy as a marker of premalignancy in surveillance of patients with ulcerative colitis. Br. J. Surg., 86, 947-950.
112. Cahill,D.P., Kinzler,K.W., Vogelstein,B. and Lengauer,C. (1999) Genetic instability and darwinian selection in tumours. Trends Cell Biol., 9, M57-M60.
113. Rajagopalan,H., Nowak,M.A., Vogelstein,B. and Lengauer,C. (2003) The significance of unstable chromosomes in colorectal cancer. Nature Rev. Cancer, 3, 695-701.
114. Zimonjic,D., Brooks,M.W., Popescu,N., Weinberg,R.A. and Hahn,W.C. (2001) Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res., 61, 8838-8844.
115. Li,R., Rasnick,D. and Duesberg,P. (2002) Correspondence re: D. Zimonjic et al. Cancer Res., 62, 6345-6349.
116. Schmitt,C.A., Fridman,J.S., Yang,M., Baranov,E., Hoffman,R.M. and Lowe,S.W. (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell, 1, 289-298.
117. Zhang,J., Schneider,C., Ottmers,L., Rodriguez,R., Day,A., Markwardt,J. and Schneider,B.L. (2002) Genomic scale mutant hunt identifies cell size homeostasis genes in S. cerevisiae. Curr. Biol. 12, 1992-2001.
118. Jorgensen,P., Nishikawa,J.L., Breitkreutz,B.J. and Tyers,M. (2002) Systematic identification of pathways that couple cell growth and division in yeast. Science, 297, 395-400.
119. Wells,W.A. (2002) Does size matter? J. Cell Biol., 158, 1156-1159.
120. Potter,C.J. and Xu,T. (2001) Mechanisms of size control. Curr. Opin. Genet. Dev., 11, 279-286.
121. Prober,D.A. and Edgar,B.A. (2001) Growth regulation by oncogenes - new insights from model organisms. Curr. Opin. Genet. Dev. 11, 19-26.
122. Stocker,H. and Hafen,E. (2000) Genetic control of cell size. Curr. Opin. Genet. Dev., 10, 529-535.
123. Neufeld,T.P. and Edgar,B.A. (1998) Connections between growth and the cell cycle. Curr. Opin. Cell Biol., 10, 784-790.
124. Day,S.J. and Lawrence,P.A. (2000) Measuring dimensions: the regulation of size and shape. Development, 127, 2977-2987.
125. Coelho,C.M. and Leevers,S.J. (2000) Do growth and cell division rates determine cell size in multicellular organisms? J. Cell Sci., 113, 2927-2934.
126. Edgar,B.A. (1999) From small flies come big discoveries about size control. Nature Cell Biol., 1, E191-E193.
127. Montagne,J. (2000) Genetic and molecular mechanisms of cell size control. Mol. Cell. Biol. Res. Commun., 4, 195-202.
128. Su,T.T. and O'Farrell,P.H. (1998) Size control: cell proliferation does not equal growth. Curr. Biol., 8, R687-R689.
129. Polymenis,M. and Schmidt,E.V. (1999) Coordination of cell growth with cell division. Curr. Opin. Genet. Dev., 9, 76-80.
130. Ekholm,S.V. and Reed,S.I. (2000) Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol., 12, 676-684.
131. Donnellan,R. and Chetty,R. (1998) Cyclin D1 and human neoplasia. Mol. Pathol., 51, 1-7.
132. Donnellan,R. and Chetty,R. (1999) Cyclin E in human cancers. FASEB J., 13, 773-780.
133. Russell,A., Thompson,M.A., Hendley,J., Trute,L., Armes,J. and Germain,D. (1999) Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene, 18, 1983-1991.
134. Moberg,K.H., Bell,D.W., Wahrer,D.C., Haber,D.A. and Hariharan,I.K. (2001) Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature, 413, 311-6.
135. Spruck,C.H., Strohmaier,H., Sangfelt,O., Muller,H.M., Hubalek,M., Muller-Holzner,E., Marth,C., Widschwendter,M. and Reed,S.I. (2002) hCDC4 gene mutations in endometrial cancer. Cancer Res., 62, 4535-4539.
136. Strohmaier,H., Spruck,C.H., Kaiser,P., Won,K.A., Sangfelt,O. and Reed,S.L. (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature, 413, 316-322.
137. Sutherland,R.L. and Musgrove,E.A. (2002) Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res., 4, 14-17.
138. Steeg,P.S. and Zhou,Q. (1998) Cyclins and breast cancer. Breast Cancer Res. Treat., 52, 17-28.
139. Reed,S.E., Spruck,C.H., Sangfelt,O., van Drogen,F., Mueller-Holzner,E., Widschwendter,M., Zetterberg,A. and Reed,S.I. (2004) Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res., 64, 795-800.
140. Tanaka,S. and Diffley,J.F. (2002) Deregulated G1-cyclin expression induces genomic instability by preventing efficient pre-RC formation. Genes Dev., 16, 2639-2649.
141. Spruck,C.H., Won,K.A. and Reed,S.I. (1999) Deregulated cyclin E induces chromosome instability. Nature, 401, 297-300.
142. Nash,P., Tang,X., Orlicky,S., Chen,Q., Gertler,F.B., Mendenhall,M.D., Sicheri,F., Pawson,T. and Tyers,M. (2001) Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature, 414, 514-521.
143. Ho,A. and Dowdy,S.F. (2002) Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr. Opin. Genet. Dev., 12, 47-52.
144. Tyers,M. (1996) The cyclin-dependent kinase inhibitor p40SIC1 imposes the requirement for Cln G1 cyclin function at Start. Proc. Natl Acad. Sci. USA, 93, 7772-7776.
145. Schneider,B.L., Yang,Q.H. and Futcher,A.B. (1996) Linkage of replication to start by the Cdk inhibitor Sic1. Science, 272, 560-562.
146. Verma,R., Annan,R.S., Huddleston,M.J., Carr,S.A., Reynard,G. and Deshaies,R.J. (1997) Phosphorylation of Sic1p by G1 Cdk required for its degradation and entry into S phase. Science, 278, 455-460.
147. Schwob,E., Bohm,T., Mendenhall,M.D. and Nasmyth,K. (1994) The B-type cyclin kinase inhibitor p40SIC1 controls the G1 to S transition in S. cerevisiae [see comments]. Cell, 79, 233-244. [Erratum, Cell, 1996, 84, 174.]
148. Nugroho,T.T. and Mendenhall,M.D. (1994) An inhibitor of yeast cyclin-dependent protein kinase plays an important role in ensuring the genomic integrity of daughter cells. Mol. Cell. Biol., 14, 3320-3328.
149. Kitanaka,C., Kato,K., Ijiri,R. et al. (2002) Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. J. Natl Cancer Inst., 94, 358-368.
150. Gurova,K.V. and Gudkov,A.V. (2003) Paradoxical role of apoptosis in tumor progression. J. Cell. Biochem., 88, 128-137.
151. Blagosklonny,M.V. (2002) Oncogenic resistance to growth-limiting conditions. Nature Rev. Cancer, 2, 221-225.
152. Greenhalgh,D.A., Wang,X.J., Donehower,L.A. and Roop,D.R. (1996) Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res., 56, 4413-4423.
153. Calin,G.A., Vasilescu,C., Negrini,M. and Barbanti-Brodano,G. (2003) Genetic chaos and antichaos in human cancers. Med. Hypotheses 60, 258-262.
154. Baum,M., Chaplain,M.A., Anderson,A.R., Douek,M. and Vaidya,J.S. (1999) Does breast cancer exist in a state of chaos? Eur. J. Cancer, 35, 886-891.
155. Cucuianu,A. (1998) Chaos in cancer? Nature Med., 4 1342-1343.
156. Coffey,D.S. (1998) Self-organization, complexity and chaos: the new biology for medicine. Nature Med, 4, 882-885.
157. Rew,D.A. (1999) Tumour biology, chaos and non-linear dynamics. Eur. J. Surg. Oncol., 25, 86-89.
158. Gleick,J. (1988) Chaos: Making a New Science. Penguin, New York, NY.
159. Braitenberg,V. (1984) Vehicles, Experiments in Synthetic Psychology. MIT Press, Cambridge, MA.
160. Miller,J.H. (1996) The relevance of bacterial mutators to understanding human cancer. Cancer Surv., 28, 141-153.
161. Miller,J.H. (1996) Spontaneous imitators in bacteria: insights into pathways of mutagenesis and repair. Annu. Rev. Microbiol., 50, 625-643.
162. Arjan,J.A., Visser,M., Zeyl,C.W., Gerrish,P.J., Blanchard,J.L. and Lenski,R.E. (1999) Diminishing returns from mutation supply rate in asexual populations. Science, 283, 404-406.
163. Giraud,A., Matic.I., Tenaillon,O., Clara,A., Radman,M., Fons,M. and Taddei,F. (2001) Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science, 291 2606-2608.
164. Sniegowski,P.D., Gerrish,P.J. and Lenski,R.E. (1997) Evolution of high mutation rates in experimental populations of E.coli. Nature, 387, 703-705.
165. Taddei,F., Radman,M., Maynard-Smith,J., Toupance,B., Gouyon,P.H. and Godelle,B. (1997) Role of mutator alleles in adaptive evolution. Nature, 387, 700-702.
166. Picard,B., Duriez,P., Gouriou,S., Matic,I., Denamur,E. and Taddei,F. (2001) Mutator natural Escherichia coli isolates have an unusual virulence phenotype. Infect. Immun., 69, 9-14.
167. Le Clerc,J.E., Li,B., Payne,W.L. and Cebula,T.A. (1996) High mutation frequencies among Escherichia coli and Salmonella pathogens. Science, 274, 1208-1211.
168. Taddei,F., Matic,I., Godelle,B. and Radman,M. (1997) To be a mutator, or how pathogenic and commensal bacteria can evolve rapidly. Trends Microbiol., 5, 427-429.
169. Rubin,H. (2001) The role of selection in progressive neoplastic transformation. Adv. Cancer Res., 83, 159-207.
170. Lee,L.W., Tsao,M.S., Grisham,J.W. and Smith,G.J. (1989) Emergence of neoplastic transformants spontaneously or after exposure to N-methyl-N′-nitro-N-nitrosoguanidine in populations of rat liver epithelial cells cultured under selective and nonselective conditions. Am. J. Pathol., 135, 63-71.
171. Greenhalgh,D.A., Welty,D.J., Strickland,J.E. and Yuspa,S.H. (1989) Spontaneous Ha-ras gene activation in cultured primary murine keratinocytes: consequences of Ha-ras gene activation in malignant conversion and malignant progression. Mol. Carcinog., 2, 199-207.
172. Schneider,B.L. and Bowden,G.T. (1992) Selective pressures and ras activation in carcinogenesis. Mol. Carcinog., 6, 1-4.
173. Bahia,H., Ashman,J.N., Cawkwell,L., Lind,M., Monson,J.R., Drew,P.J. and Greenman,J. (2002) Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization. Int. J. Oncol. 20, 489-494.
174. Osborne,C.K., Hobbs,K. and Trent,J.M. (1987) Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res. Treat., 9, 111-121.
175. Yuan,J. and Glazer,P.M. (1998) Mutagenesis induced by the tumor microenvironment. Mutat. Res., 400, 439-446.
176. Yu,J.L., Rak,J.W., Coomber,B.L., Hicklin,D.J. and Kerbel,R.S. (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science, 295, 1526-1528.
177. Giuriato,S. and Felsher,D.W. (2003) How cancers escape their oncogene habit. Cell Cycle, 2, 329-332.
178. Felsher,D.W. (2003) Cancer revoked: oncogenes as therapeutic targets. Nature Rev. Cancer, 3, 375-380.
179. Zvulunov,A., Peleg,L., Carlebach,R. and Ashkenazi,I.E. (2002) Chemotoxicity and survival of tumor-bearing mice under exposure to randomized photoperiodic regimen. Life Sci., 72, 237-245.
180. Wu,W., Yamaura,T., Murakami,K., Murata.J., Matsumoto,K., Watanabe,H. and Saiki,I. (2000) Social isolation stress enhanced liver metastasis of murine colon 26-L5 carcinoma cells by suppressing immune responses in mice. Life Sci., 66, 1827-1838.
181. Sampath,J., Adachi,M., Hatse,S., Naesens,L., Balzarini,J., Flatley,R.M., Matherly,L.H. and Schuetz,J.D. (2002) Role of MRP4 and MRP5 in biology and chemotherapy. American Association of Pharmaceutical Scientists (AAPS) PharmSci, 4, E14.
182. Riou,M., Guegnard,F., Le Vern,Y. and Kerboeuf,D. (2003) Modulation of the multidrug resistance (MDR) system in the nematode Haemonchus contortus by changing cholesterol content: effects on resistance to anthelmintics. J. Antimicrob. Chemother., 52, 180-187.
183. Dellavalle,R.P., Nicholas,M.K. and Schilling,L.M. (2003) Melanoma chemoprevention: a role for statins or fibrates? Am. J. Ther. 10, 203-210.
184. Fagnoni,F.F., Lozza,L., Zibera,C. et al. (2002) T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology, 106, 27-37.
185. Bardos,T., Mikecz,K., Finnegan,A., Zhang,J. and Glant,T.T. (2002) T and B cell recovery in arthritis adoptively transferred to SCID mice: antigen-specific activation is required for restoration of autopathogenic CD4+ Th1 cells in a syngeneic system. J. Immunol., 168, 6013-6021.
186. Breivik,J. (2001) Don't stop for repairs in a war zone: Darwinian evolution unites genes and environment in cancer development. Proc. Natl Acad. Sci. USA, 98, 5379-5381.
187. Evan,G.I. and Vousden,K.H. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-348.
188. Tam,S.W. and Schlegel,R. (1992) Staurosporine overrides checkpoints for mitotic onset in BHK cells. Cell Growth Differ., 3, 811-817.
189. Bunch,R.T. and Eastman,A. (1996) Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res., 2, 791-797.
190. Lau,C.C. and Pardee,A.B. (1982) Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc. Natl Acad. Sci. USA 79, 2942-2946.
191. Eastman,A. (2004) Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell. Biochem., 91, 223-231.
192. Grant,S. and Roberts,J.D. (2003) The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resistance Update, 6, 15-26.
193. Cartee,L., Wang,Z., Decker,R.H., Chellappan,S.P., Fusaro,G., Hirsch,K.G., Sankala,H.M., Dent,P. and Grant,S. (2001) The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res., 61, 2583-2591.
194. Sax,J.K., Dash,B.C., Hong,R., Dicker,D.T. and El-Deiry,W.S. (2002) The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle, 1, 90-96.
195. Pelengaris,S., Khan,M. and Evan,G. (2002) c-MYC: more than just a matter of life and death. Nature Rev. Cancer, 2, 764-776.
196. Golub,T.R. (2003) Mining the genome for combination therapies. Nature Med., 9, 510-511.
197. Eastman,A. and Rigas,J.R. (1999) Modulation of apoptosis signaling pathways and cell cycle regulation. Semin. Oncol., 26 7-16; Discussion, 41-42.
198. Li,R. and Murray,A.W. (1991) Feedback control of mitosis in budding yeast. Cell, 66, 519-531.
199. Hoyt,M.A., Totis,L. and Roberts,B.T. (1991) S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell, 66, 507-517.
200. Nowak,M.A. and Sigmund,K. (2004) Evolutionary dynamics of biological games. Science, 303, 793-799.